Shares of Agnico Eagle Mines Ltd (TSX:AEM) rose about 5.5% in New York trading after the gold producer reported a modest fourth-quarter earnings beat and maintained its three-year production outlook.
Agnico posted adjusted fourth-quarter 2025 earnings per share of $2.70, slightly ahead of the $2.68 consensus estimate, while adjusted EBITDA of $2.51 billion also topped expectations. The beat was driven by stronger-than-expected gold sales.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported fourth quarter 2025 results that exceeded Wall Street expectations, sending its shares up about 11% on Friday.
The company posted a net loss of $2.11 per share on revenue of $678 million, compared with analysts’ consensus of a $2.60 loss on revenue near $660 million.
Roku Inc (NASDAQ:ROKU) shares climbed almost 5% following the company’s release of fourth quarter 2025 results, which exceeded Wall Street expectations and highlighted growth in its platform business.
The company reported revenue of $1.395 billion for Q4, a 16% increase from the same period a year earlier and above analyst forecasts of $1.35 billion.
HIVE Digital Technologies (TSX-V:HIVE, NASDAQ:HIVE, FRA:YO0, BVC:HIVECO) announced that its BUZZ High Performance Computing unit has signed customer agreements representing about $30 million in total contract value over two-year fixed terms, marking what the company described as progress in its artificial intelligence cloud strategy.
BUZZ, the company’s Canadian Tier-III high-performance computing data center platform, is expanding as HIVE’s AI-focused business alongside its existing Tier-I hashrate services operations. The company said the new contracts support the initial phase of BUZZ’s AI-optimized GPU deployment at its Canada West site in Manitoba.
Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the biotechnology company works to transition toward commercialization of its multiple sclerosis pipeline.
Shares jumped nearly 28% on Friday morning, reaching $1.11 in New York.
Draftkings Inc (NASDAQ:DKNG) shares fell more than 12% after the company reported fourth quarter 2025 results that included a significant earnings-per-share miss and cautious fiscal 2026 guidance.
The sports betting and online gaming company posted Q4 revenue of $1.99 billion, up 43% from $1.39 billion in the same period last year, surpassing analyst expectations of $1.97 billion.
Instacart (NASDAQ:CART) shares jumped more than 14% in early trading on Friday after the grocery delivery company posted its strongest quarterly volume performance in three years, even as profit margins came under pressure.
For the fourth quarter, gross transaction value (GTV) rose 14% year-over-year to $9.85 billion, while orders climbed 16% to 89.5 million. Total revenue increased 12% to $992 million, slightly above Wall Street expectations of $974 million.
Pinterest Inc (NYSE:PINS) shares fell more than 20% to about $15 on Friday morning after the company issued a softer-than-expected outlook as well as disappointing fourth quarter earnings.
The social media platform guided first quarter 2026 revenue to between $951 million and $971 million, representing year-over-year growth of about 11% to 14% but below the Wall Street consensus of $980 million. The company said it expects first-quarter adjusted EBITDA of $166 million to $186 million.
Shares of Airbnb Inc (NASDAQ:ABNB, XETRA:6Z1) rose nearly 7% on Friday morning after the vacation rental platform reported fourth-quarter revenue that beat Wall Street expectations and issued a stronger-than-expected outlook for the start of 2026.
Airbnb reported fourth-quarter earnings per share of $0.56, below analysts’ expectations of $0.66. But revenue rose 12% year-over-year to $2.78 billion, topping the $2.71 billion consensus estimate.
Coinbase Global Inc (NASDAQ:COIN) reported fourth quarter 2025 results that fell short of analyst expectations as crypto market activity softened during the period.
The company posted revenue of $1.78 billion for the quarter, below the $1.85 billion consensus estimate, while earnings per share came in at $0.66 versus the $1.05 forecast. Total revenue declined 5% quarter-over-quarter, reflecting weaker trading conditions late in the year.
Shares in CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) rose 3% to 1.08p after the company announced it would discontinue its United States Food and Drug Administration establishment licence and device listing for its Parsortix system.
The Guildford-based group, which provides circulating tumour cell intelligence tests and services to support cancer research and drug development, said the decision reflected its revised business model and customer usage patterns.